Copyright
©The Author(s) 2015.
World J Hepatol. Oct 18, 2015; 7(23): 2449-2458
Published online Oct 18, 2015. doi: 10.4254/wjh.v7.i23.2449
Published online Oct 18, 2015. doi: 10.4254/wjh.v7.i23.2449
Table 1 Differences between the studies made on the correlation between programmed death-1 expression and clinical outcome
Ref. | No. of patients | Mode of transfection | Symptoms | PD-1 expression levels in acute infection | PD-1 expression levels in resolved patients |
Urbani et al[16] | 19 | Sexually transmission | Symptomatic | High | Decreased |
Kasprowicz et al[17] | 37 | Sexually transmission | Symptomatic | High | Irrespective |
Rutebemberwa et al[62] | 20 | Injection drug use | Asymptomatic | High | Decreased |
- Citation: Salem ML, El-Badawy A. Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy. World J Hepatol 2015; 7(23): 2449-2458
- URL: https://www.wjgnet.com/1948-5182/full/v7/i23/2449.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i23.2449